Role of NGF in breast cancer angiogenesis

Notre laboratoire a montré précédemment que le facteur NGF est produit par les cellules de cancer du sein et non par les cellules épithéliales mammaires normales. De plus, le NGF est un puissant facteur mitogène et anti-apoptotique pour les cellules de cancer du sein. Dans le cadre de ce travail, nous avons voulu déterminer l’implication du NGF dans l’angiogenèse tumorale ainsi que les mécanismes mis en jeu. Nous avons montré que le NGF est un puissant facteur angiogénique ayant un rôle essentiel dans la vascularisation tumorale dans des modèles expérimentaux chez la souris SCID. De plus, le NGF exerce des effets pléiotropiques sur les cellules endothéliales in vitro avec une intensité similaire au VEGF, le facteur angiogénique prototypique. Par ailleurs, l’effet stimulateur du NGF sur l’invasion des cellules endothéliales dépend de l’activation de son récepteur à activité tyrosine kinase TrkA et des voies de signalisation en aval telles que les voies PI3K/Akt et NO synthase. Enfin, nous avons montré que l’effet angiogénique du NGF est dévolu en partie à une activité du VEGF, puisque la neutralisation du VEGF à l’aide d’un anticorps conduit à une diminution de l’angiogenèse induite par le NGF. Ceci peut s’expliquer par le faite que le NGF augmente la sécrétion du VEGF par les cellules endothéliales et les cellules de cancer du sein. De façon intéressante, nous avons montré que la neurotrophine NT-4/5 exerce également un effet angiogénique in vitro.Our laboratory has previously shown that the neurotrophic factor NGF (Nerve Growth Factor) is specifically produced by breast cancer cells and not by normal mammary epithelial cells. Furthermore, NGF is a powerful mitogenic and anti-apoptotic factor for breast cancer cells. To investigate the implication of NGF in breast cancer development, we wanted to determine its possible role in tumor angiogenesis and the underlying mechanisms. First, we showed that NGF is a powerful angiogenic factor playing an essential role in tumor vascularization in experimental models performed using SCID mice. Furthermore, NGF exerts pleiotropic effects on endothelial cells in vitro with intensity similar to VEGF. Moreover, NGF-stimulated invasion of endothelial cells depends on the activation of its receptor tyrosine kinase receptor TrkA and the downstream signaling pathways such as PI3K / Akt and NO synthase. Interestingly, we showed that angiogenic effect of NGF is partially due to VEGF, as NGF can increase secretion of VEGF by both endothelial cells and breast cancer cells; furthermore, neutralizing antibody against VEGF strongly reduces NGF-induced angiogenesis. In addition, we showed that neurotrophin factor NT-4/5 also exerts an angiogenic effect in vitro

Rôle du NGF dans l'angiogenèse du cancer du sein

Notre laboratoire a montré précédemment que le facteur NGF est produit par les cellules de cancer du sein et non par les cellules épithéliales mammaires normales. De plus, le NGF est un puissant facteur mitogène et anti-apoptotique pour les cellules de cancer du sein. Dans le cadre de ce travail, nous avons voulu déterminer l implication du NGF dans l angiogenèse tumorale ainsi que les mécanismes mis en jeu. Nous avons montré que le NGF est un puissant facteur angiogénique ayant un rôle essentiel dans la vascularisation tumorale dans des modèles expérimentaux chez la souris SCID. De plus, le NGF exerce des effets pléiotropiques sur les cellules endothéliales in vitro avec une intensité similaire au VEGF, le facteur angiogénique prototypique. Par ailleurs, l effet stimulateur du NGF sur l invasion des cellules endothéliales dépend de l activation de son récepteur à activité tyrosine kinase TrkA et des voies de signalisation en aval telles que les voies PI3K/Akt et NO synthase. Enfin, nous avons montré que l effet angiogénique du NGF est dévolu en partie à une activité du VEGF, puisque la neutralisation du VEGF à l aide d un anticorps conduit à une diminution de l angiogenèse induite par le NGF. Ceci peut s expliquer par le faite que le NGF augmente la sécrétion du VEGF par les cellules endothéliales et les cellules de cancer du sein. De façon intéressante, nous avons montré que la neurotrophine NT-4/5 exerce également un effet angiogénique in vitro.Our laboratory has previously shown that the neurotrophic factor NGF (Nerve Growth Factor) is specifically produced by breast cancer cells and not by normal mammary epithelial cells. Furthermore, NGF is a powerful mitogenic and anti-apoptotic factor for breast cancer cells. To investigate the implication of NGF in breast cancer development, we wanted to determine its possible role in tumor angiogenesis and the underlying mechanisms. First, we showed that NGF is a powerful angiogenic factor playing an essential role in tumor vascularization in experimental models performed using SCID mice. Furthermore, NGF exerts pleiotropic effects on endothelial cells in vitro with intensity similar to VEGF. Moreover, NGF-stimulated invasion of endothelial cells depends on the activation of its receptor tyrosine kinase receptor TrkA and the downstream signaling pathways such as PI3K / Akt and NO synthase. Interestingly, we showed that angiogenic effect of NGF is partially due to VEGF, as NGF can increase secretion of VEGF by both endothelial cells and breast cancer cells; furthermore, neutralizing antibody against VEGF strongly reduces NGF-induced angiogenesis. In addition, we showed that neurotrophin factor NT-4/5 also exerts an angiogenic effect in vitro.LILLE1-Bib. Electronique (590099901) / SudocSudocFranceF

Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways.

International audienceBACKGROUND: Although several anti-angiogenic therapies have been approved in the treatment of cancer, the survival benefits of such therapies are relatively modest. Discovering new molecules and/or better understating signaling pathways of angiogenesis is therefore essential for therapeutic improvements. The objective of the present study was to determine the involvement of nerve growth factor (NGF) in breast cancer angiogenesis and the underlying molecular mechanisms. RESULTS: We showed that both recombinant NGF and NGF produced by breast cancer cells stimulated angiogenesis in Matrigel plugs in immunodeficient mice. NGF strongly increased invasion, cord formation and the monolayer permeability of endothelial cells. Moreover, NGF-stimulated invasion was under the control of its tyrosine kinase receptor (TrkA) and downstream signaling pathways such as PI3K and ERK, leading to the activation of matrix metalloprotease 2 and nitric oxide synthase. Interestingly, NGF increased the secretion of VEGF in both endothelial and breast cancer cells. Inhibition of VEGF, with a neutralizing antibody, reduced about half of NGF-induced endothelial cell invasion and angiogenesis in vivo. CONCLUSIONS: Our findings provided direct evidence that NGF could be an important stimulator for breast cancer angiogenesis. Thus, NGF, as well as the activated signaling pathways, should be regarded as potential new targets for anti-angiogenic therapy against breast cancer

Ku86 is important for TrkA overexpression-induced breast cancer cell invasion

International audiencePurpose: We have recently shown that breast tumors express high levels of TrkA compared with normal breast tissues, with TrkA overexpression enhancing breast cancer cell invasion in vitro and metastasis in animal models. In this study, we tried to identify molecules involved in TrkA overexpression-mediated biological effects in breast cancer cellsExperimental design: We used a proteomic-based approach to identify proteins involved in TrkA overexpression-stimulated invasion of MDA-MB-231 breast cancer cells. Proteins from control and TrkA overexpressing cells were separated using a cup-loading two-dimensional electrophoresis system before MALDI and LC-MS/MS mass spectrometry analysisResults Among several putative regulated proteins, Ku86 was found increased in TrkA overexpressing cells. Moreover, Ku86 was co-immunoprecipitated with TrkA, suggesting the interaction of these two proteins in TrkA overexpressing cells. Interestingly, inhibition with small-interfering RNA and neutralizing antibodies showed that Ku86 was required for TrkA-stimulated cell invasionConclusions and clinical relevance. These data allowed the identification of Ku86 as a new player involved in metastasis in breast cancer cells. Our findings suggest that TrkA and its down stream signaling pathways should be regarded as potential new targets for the development of future breast cancer therap